Bronchial Mucosa
Bronchial Mucosa - Related Videos
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
0 Views •
Cited by 4 •
2010
Bronchial thermoplasty is a non-drug procedure for severe persistent asthma that delivers thermal energy to the airway wall in a precisely controlled manner to reduce excessive airway smooth muscle. Reducing airway smooth muscle decreases the ability of the airways to constrict, thereby reducing the frequency of asthma attacks.
11:54
Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples
0 Views •
Cited by 53 •
2018
This manuscript describes the use of nasal and bronchial absorption techniques, specifically using synthetic absorptive matrices (SAM) to sample the mucosal lining fluid (MLF) of the upper and lower airway. These methods provide better standardization and tolerability than existing respiratory sampling techniques.
14:32
Primary Human Bronchial Epithelial Cells Grown from Explants
0 Views •
Cited by 20 •
2010
Here we describe a detailed method for growing primary human bronchial epithelial cells from explants of human bronchial airway tissue including differentiated growth on an air-liquid interface. This method provides an abundant source of primary cells for investigating the role of the airway epithelium in human lung health and disease.
04:46
Isolation of Lymphocytes from Mouse Genital Tract Mucosa
0 Views •
Cited by 10 •
2012
An efficient way to isolate lymphocytes from mouse genital tract is described. This method takes advantage of enzyme digestion and Percoll gradient separation to allow efficient isolation. This technique is also adaptable to for use in other...
06:16
Cryosectioning Method for Microdissection of Murine Colonic Mucosa
0 Views •
Cited by 4 •
2015
Here we describe a simple method for the isolation of spatially distinct murine colonic epithelial surface cells from the underlying crypt-base cells.
FAQs
Ciliary beating provides the directional component of mucociliary clearance: it moves mucus carrying trapped particles toward the throat. This means airway protection depends not only on mucus being present, but also on coordinated movement across the epithelial surface. In pharmacology, treatments that change mucus production or ciliary clearance can alter how long inhaled substances remain in contact with bronchial tissue.
Epithelial and immune signaling gives the mucosa an active response to inhaled irritants and pathogens. These signals can influence local airway conditions rather than serving solely as a passive barrier. Their pharmacological importance is that drug effects may be evaluated in relation to inflammation and host defense, especially when studying therapies intended to modify airway disease or infection-related responses.
The bronchial mucosa affects inhaled drug action at several linked stages: deposition on the airway surface, dissolution in its moist environment, and passage across epithelial barriers. Each stage determines whether a substance can reach an airway target. Consequently, pharmacological evaluation must consider the mucosal interface as part of drug delivery, not merely as tissue surrounding the eventual site of action.
Drug interactions with the mucosa can produce different pharmacological consequences. A medicine may be examined for effects on mucus production, inflammation, or mucociliary clearance, while the mucosa simultaneously influences the medicine’s access to airway targets. Distinguishing these directions of interaction helps explain both intended airway effects and changes in local conditions that may alter inhaled drug behavior.
A pharmacological assessment can trace an inhaled substance from airway deposition to dissolution and epithelial passage, then consider whether it reaches its intended airway target. The same assessment can examine changes in mucus production, inflammation, and mucociliary clearance after exposure. This combined approach connects delivery behavior with biological response and is relevant when comparing potential airway treatments.
Bronchial mucosa is relevant to therapies for asthma, chronic obstructive pulmonary disease, and airway infection because it links inhaled drug delivery with airway defense and local responses. Investigators can ask whether a treatment reaches the appropriate airway target and how it affects mucus, inflammation, or clearance. These outcomes help frame the treatment’s potential usefulness in disease-focused pharmacology.
Clearance can change how long mucus and trapped material remain on the bronchial surface. Because the mucosa also affects deposition, dissolution, and epithelial passage, altered clearance may influence the opportunity for an inhaled medicine to interact with airway tissue. Measuring or considering this process therefore supports a more complete interpretation of local pharmacological effects.